Provided by Tiger Trade Technology Pte. Ltd.

Jade Biosciences

13.77
-0.2800-1.99%
Pre-market: 13.75-0.0200-0.15%07:30 EDT
Volume:1.07M
Turnover:14.86M
Market Cap:875.74M
PE:-5.88
High:14.58
Open:13.97
Low:13.59
Close:14.05
52wk High:28.00
52wk Low:8.16
Shares:63.60M
Float Shares:47.12M
Volume Ratio:1.43
T/O Rate:2.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3433
EPS(LYR):-3.1931
ROE:-89.18%
ROA:-33.59%
PB:0.30
PE(LYR):-4.31

Loading ...

Analyst Julian Harrison Lifts Jade Biosciences Price Target to $77 and Reiterates Buy on Strong Pipeline and De-Risked IgA Program

TIPRANKS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Aug 11

Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating

MT Newswires Live
·
Aug 10

Earnings Flash (JBIO) Jade Biosciences Posts Q2 Loss $0.76 a Share, vs. FactSet Est of $0.63 Loss

MT Newswires Live
·
Aug 10

Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate

Benzinga Earnings
·
Aug 10

Jade Biosciences Q2 FY26 Net Loss Widens to $55.8 Million

Reuters
·
Aug 10

Jade Biosciences, Inc Q2 Basic EPS USD -0.76

THOMSON REUTERS
·
Aug 10

Jade Biosciences, Inc Q2 Net Income USD -55.8 Million VS. Ibes Estimate USD -42.1 Million

THOMSON REUTERS
·
Aug 10

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 10

Jade Biosciences Inc Expected to Post a Loss of 64 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Jade Biosciences - Enters Exclusive Worldwide License Agreement with Paragon Therapeutics - SEC Filing

Reuters
·
Jul 07

Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued?

Simply Wall St.
·
Jul 03

Jade Biosciences - to Pay Paragon Low to Mid-single-digit Percentage Royalties on Net Sales of Licensed Products - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences - Paragon Barred from New Campaigns Targeting Licensed Target for at Least Five Years - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences - to Pay up to $22 Mln in Milestone Payments to Paragon - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences - Enters Exclusive Worldwide License Agreement with Paragon Therapeutics - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences Secures Exclusive Antibody License Agreement

TIPRANKS
·
Jul 02

Jade Biosciences Licenses Paragon Antibody Program, with up to $22 Million in Milestones

Reuters
·
Jul 02

Jade Biosciences Director Mark Eisner Files Initial Beneficial Ownership Statement

Reuters
·
Jun 27

Jade Biosciences Announces Appointment of Mark Eisner, M.d., M.p.h., to Board of Directors

THOMSON REUTERS
·
Jun 26